Biotech’s Big Gamble Fails: Insights and Implications
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
- Latest
- Trending
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Discover the booming VRET market, driven by tech advances and mental health needs, expected to grow at a 33.90% CAGR ...
"Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...
Avidity Biosciences sees share ownership shift as MacLean reduces holding under Rule 10b5-1 Plan; positive sector developments bolster outlook.
Tempus AI sold 11M shares at $37 each, launched in 2015, focuses on medical testing, with revenue growth from $320.7M ...
Iovance Biotherapeutics has the potential to become a multiproduct company, and even if its stock doesn't soar quickly, it's still ...
Swiss chemist Albert Hofmann first synthesized LSD in the 1930s. While research eventually halted, the drug is now being decriminalized ...
Phase 1 biotech Boundless Bio raised $100 million at a $396 million market cap. Two IPOs are scheduled for the ...
Delve into a comprehensive financial analysis of Cabaletta Bio Inc, a key player in the NASDAQ exchange, with a strong ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.